後藤 穣 ごとう みのる 先生

来歴等

略歴

1991年 日本医科大学 卒業
2004年 日本医科大学 耳鼻咽喉科学 講師
2011年 日本医科大学耳鼻咽喉科学 准教授
2024年 日本医科大学花粉症学講座 教授
2025年 日本医科大学大学院医学研究科 頭頸部・感覚器科学分野 教授

論文

• 1. Real-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan. Allergy Asthma Proc. 2025 Jan 1;46(1):59-69.

  Gotoh M, Maekawa Y, Saito S, Kato N, Horikawa E, Nishino N.

• 2. From the genesis to the present: The evolution of sublingual immunotherapy for cedar pollinosis. Allergol Int. 2024 Oct;73(4):494-500.

  Gotoh M, Kaminuma O, Okubo K.

• 3. Same dose of Japanese cedar pollen sublingual immunotherapy tablets is optimal for allergic rhinitis caused by either Japanese cedar or Japanese cypress pollen. Allergy. 2023 Feb;78(2):563-568.

  Gotoh M, Kurokawa T, Yonekura S, Okano M, Maekawa Y, Okamoto Y, Okubo K.

• 4. Sublingual Immunotherapy: How Sublingual Allergen Administration Heals Allergic Diseases; Current Perspective About the Mode of Action. Pathogens. 2021 Feb 2;10(2):147.

  Gotoh M, Kaminuma O.

• 5. Basophil-expressing genes related with the efficacy of sublingual immunotherapy. J Nippon Med Sch. 2019 Sep 30. doi: 10.1272

  Gotoh M, Kaminuma O, Hiroi T, Okubo K.

• 6. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet. Allergol Int. 2019 Aug 14.

  Gotoh M, Okubo K, Yuta A, Ogawa Y, Nagakura H, Ueyama S, Ueyama T, Kawashima K, Yamamoto M, Fujieda S, Sakashita M, Sakamoto H, Iwasaki N, Mori E, Endo T, Ohta N, Kitazawa H, Okano M, Asako M, Takada M, Terada T, Inaka Y, Yonekura S, Matsuoka T, Kaneko S, Hata H, Hijikata N, Tanaka H, Masuyama K, Okamoto Y.

• 7. Long-term efficacy and dose-finding trial of Japanese cedar pollen SLIT tablet. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1287-1297.

  Gotoh M, Yonekura S, Imai T, Kaneko S, Horikawa E, Konno A, Okamoto Y, Okubo K.

• 8. Microarray-based multivariate analysis of the effectiveness of sublingual immunotherapy for cedar pollinosis. Allergy Asthma Immunol Res. 2018 Sep;10(5):562-569.

  Gotoh M, Kaminuma O, Hiroi T, Okubo K.

• 9. スギ花粉症に対するアレルゲン免疫療法の治療目標の検討－TO-194SL（シダトレン®スギ花粉舌下液）第Ⅲ相臨床試験結果から－. アレルギー67(7).938-947, 2018

  後藤穣，大久保公裕，岡本美孝，米倉修二，金子真也，今野昭義.

• 10. Involvement of taste receptors in the effectiveness of sublingual immunotherapy. Allergol Int. 2018 Jul;67(3):421-424.

  Gotoh M, Kaminuma O, Nakaya A, Katayama K, Watanabe N, Saeki M, Nishimura T, Kitamura N, Okubo K, Hiroi T.

• 11. Identification of biomarker sets for predicting the efficacy of sublingual immunotherapy against pollen-induced allergic rhinitis. Int Immunol. 2017 Jun 1;29(6):291-300.

  Gotoh M, Kaminuma O, Nakaya A, Katayama K, Motoi Y, Watanabe N, Saeki M, Nishimura T, Kitamura N, Yamaoka K, Okubo K, Hiroi T.

• 12. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int. 2017 Jan;66(1):97-105.

  Okubo K, Gotoh M, Asako M, Nomura Y, Togawa M, Saito A, Honda T, Ohashi Y.

• 13. Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis. Int Arch Allergy Immunol. 2015 Apr 18;166(3):177-188.

  Okamoto Y, Okubo K, Yonekura S, Hashiguchi K, Goto M, Otsuka T, Murata T, Nakao Y, Kanazawa C, Nagakura H, Okawa T, Nakano K, Hisamitsu M, Kaneko S, Konno A.

• 14. Severity Assessment of Japanese Cedar Pollinosis Using the Practical Guideline for the Management of Allergic Rhinitis in Japan and the Allergic Rhinitis and its Impact on Asthma Guideline. Allergol Int. 2013 Jun;62(2):181-9.

  Gotoh M, Yuta A, Okano M, Ohta N, Matsubara A, Okubo K.

• 15. Non invasive biological evaluation of response to pranlukast treatment in pediatric patients with Japanese cedar pollinosis. Allergy Asthma Proc. 33:459-466, 2012

  Gotoh M, Okubo K, Hashiguchi K, Wakabayashi K, Kanzaki S, Tanaka N, Fujioka M, Kawashima K, Suematsu K, Sasaki K, Iwasaki M, Yamamotoya H.

• 16. Sublingual immunotherapy for Japanese cedar pollinosis: current status in Japan. Clinical & Experimental Allergy Reviews. 2012; 12, 36–40

  Gotoh M, Okubo K.

• 17. Delay of onset of symptoms of Japanese cedar pollinosis by treatment with a leukotriene receptor antagonist. Allergol Int. 2011 Nov;60(4):483-9.

  Gotoh M, Suzuki H, Okubo K.

• 18. Efficacy of epinastine hydrochloride for antigen-provoked nasal symptoms in subjects with orchard grass pollinosis. Allergol Int. 2011 Mar;60(1):69-77

  Gotoh M, Hashiguchi K, Okubo K.

• 19. Clinical pharmacology study of the corticosteroid nasal spray dexamethasone cipecilate (NS-126): examination of the durability of efficacy in the nasal induction test. Expert Opin. Investig. Drugs. 2010.

  Gotoh M, Okubo K, Okuda M. Hamada C.

• 20. Efficacy of oral administration of a heat-killed Lactobacillus gasseri OLL2809 on patients of Japanese cedar pollinosis with high Japanese-cedar pollen-specific IgE. Biosci Biotechnol Biochem. 2009 Sep;73(9):1971-7. Epub 2009 Sep 7.

  Gotoh M, Sashihara T, Ikegami S, Yamaji T, Kino K, Orii N, Taketomo N, Okubo K.

• 21. アレルギー免疫療法の普及をめざして－現状と将来－スギ花粉症に対する舌下免疫療法．耳鼻免疫アレルギー　25, 256-261, 2007

  後藤穣、大久保公裕、島田健一、八木聰明、奥田稔.

• 22. Inhibitory effects of facemasks and eyeglasses on invasion of pollen particles in the nose and eye: a clinical study. Rhinology, 43, 266-270, 2005

  Gotoh M, Okubo K, Okuda M.

• 23. Sublingual Immunotherapy for Japanese Cedar Pollinosis. Allergology International. 2005;54:167-171

  Gotoh M, Okubo K.

• 24. Repeated antigen challenge in patients with perennial allergic rhinitis to house dust mites. Allergology International (2003) 52: 207-212

  Gotoh M, Okubo K, Okuda M.

• 25. ペプチド免疫療法の現状. 日鼻誌41(1):94-96, 2002

  後藤穣、大久保公裕、中村伸、山地健人 他.

• 26. ブラディキニン鼻誘発反応におけるアンギオテンシン変換酵素の関与：正常者と鼻アレルギー患者の比較．日耳鼻102：218-225, 1999．

  後藤穣.

• 27. 聴神経腫瘍症例におけるABRの陽性率. 耳鼻42：7-11，1996

  後藤穣、馬場俊吉、八木聰明.

• 28. 鼻粘膜上皮細胞のサイトカイン産生に対する塩酸アゼラスチンの効果. 耳鼻免疫アレルギー15（1）20-26、1997

  後藤穣、滝沢竜太、大久保公裕 他.

SNS・ブログ等

• その他メディア
  • 日本医科大学 耳鼻咽喉科学教室HP